Maxcyte (MXCT) Price to Sales (2021 - 2026)

Maxcyte (MXCT) has reported Price to Sales for 6 consecutive years, with 17.95 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 34.27% year-over-year to 17.95 in Q2 2026; TTM through Jun 2026 was 4.2, a 35.31% decrease from a year earlier, with the FY2025 full-year figure at 5.01, down 55.98% from the prior year.
• Price to Sales was 17.95 for Q2 2026 at Maxcyte, up from 7.8 in the prior quarter.
• Over five years, Price to Sales peaked at 62.24 in Q3 2022 and troughed at 7.8 in Q1 2026.
• A 5-year average of 39.38 and a median of 39.88 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales surged 62.18% in 2024 and plunged 72.09% in 2026, its largest moves.
• Over 5 years, Price to Sales stood at 45.0 in 2022, then sank by 30.69% to 31.19 in 2023, then surged by 62.18% to 50.59 in 2024, then tumbled by 55.18% to 22.67 in 2025, then slipped by 20.82% to 17.95 in 2026.
• The last three Price to Sales figures came in at 17.95 (Q2 2026), 7.8 (Q1 2026), and 22.67 (Q4 2025), per Business Quant data.